Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.

Authors: Nataliya Mar, Siamak Daneshmand, David Joseph Benjamin, Anishka D'souza, Michael A. Daneshvar, Arash Rezazadeh

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4622

Source: Full article

---

Abstract

TPS4622